Join

Compare · BOLT vs LLY

BOLT vs LLY

Side-by-side comparison of Bolt Biotherapeutics Inc. (BOLT) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BOLT and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • LLY is the larger of the two at $1.06T, about 115858.0x BOLT ($9.1M).
  • Over the past year, BOLT is down 21.1% and LLY is up 47.1% - LLY leads by 68.2 points.
  • LLY has been more active in the news (21 items in the past 4 weeks vs 4 for BOLT).
  • LLY has more recent analyst coverage (25 ratings vs 6 for BOLT).
PerformanceBOLT-21.10%LLY+46.24%
2025-06-05+0.00%2026-06-03
MetricBOLTLLY
Company
Bolt Biotherapeutics Inc.
Eli Lilly and Company
Price
$4.75-6.13%
$1125.46+3.97%
Market cap
$9.1M
$1.06T
1M return
-4.62%
+13.86%
1Y return
-21.10%
+47.14%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
4
21
Recent ratings
6
25
BOLT

Bolt Biotherapeutics Inc.

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

LLY

Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Latest BOLT

Latest LLY